Quarterly ResultMay 13, 2026, 04:14 PM
Bionano Genomics Q1 Net Loss $8.3M; Substantial Going Concern Doubt
AI Summary
Bionano Genomics, Inc. reported a net loss of $8.3 million for the first quarter of 2026, a significant increase from $3.1 million in the prior year, despite a modest 3.6% rise in total revenue to $6.7 million. The company also disclosed substantial doubt about its ability to continue as a going concern within the next twelve months, highlighting its reliance on securing additional funding to address recurring losses and negative cash flows.
Key Highlights
- Substantial doubt about Bionano Genomics' ability to continue as a going concern within 12 months.
- Net loss increased to $8.3 million in Q1 2026 from $3.1 million in Q1 2025.
- Total revenue rose 3.6% to $6.7 million in Q1 2026 from $6.5 million in Q1 2025.
- Product revenue increased 1.5% to $6.1 million, driven by instruments (+39.6%) and consumables (+20.1%).
- Selling, general and administrative expenses decreased 11.3% to $8.0 million.
- Net cash used in operating activities increased to $5.7 million in Q1 2026 from $2.8 million in Q1 2025.
- Cash and cash equivalents were $3.4 million as of March 31, 2026.
- $10.3 million principal outstanding on convertible debentures as of March 31, 2026.
Price Impact
More from BNGO